(IMCR) Immunocore Holdings - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.443m USD | Total Return: -7.6% in 12m

Cancer Immunotherapies, T-Cell Engagers, Antivirals, Autoimmune Medicines
Total Rating 18
Safety 49
Buy Signal -0.61
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.44B
Avg Turnover: 8.12M
Risk 3d forecast
Volatility40.6%
VaR 5th Pctl7.06%
VaR vs Median5.58%
Reward TTM
Sharpe Ratio-0.05
Rel. Str. IBD12.7
Rel. Str. Peer Group11.8
Character TTM
Beta0.393
Beta Downside0.495
Hurst Exponent0.468
Drawdowns 3y
Max DD67.45%
CAGR/Max DD-0.29
CAGR/Mean DD-0.46
EPS (Earnings per Share) EPS (Earnings per Share) of IMCR over the last years for every Quarter: "2021-03": -0.92, "2021-06": -1.04, "2021-09": -0.93, "2021-12": -91, "2022-03": -37, "2022-06": -14, "2022-09": 12, "2022-12": -54, "2023-03": -35, "2023-06": -0.37, "2023-09": 4, "2023-12": -32.22, "2024-03": -0.49, "2024-06": -0.23, "2024-09": 0.17, "2024-12": -0.3714, "2025-03": -0.49, "2025-06": -0.2, "2025-09": -0.0035, "2025-12": -0.6, "2026-03": 0.25,
Last SUE: 1.39
Qual. Beats: 1
Revenue Revenue of IMCR over the last years for every Quarter: 2021-03: 8.27, 2021-06: 5.733, 2021-09: 5.924, 2021-12: 6.593, 2022-03: 22.474, 2022-06: 40.141221, 2022-09: 48.434163, 2022-12: 48.874604, 2023-03: 44.209019, 2023-06: 47.174566, 2023-09: 53.559124, 2023-12: 56.005996, 2024-03: 70.502, 2024-06: 75.4, 2024-09: 80.248, 2024-12: 84.052, 2025-03: 93.881, 2025-06: 97.964, 2025-09: 103.693, 2025-12: 77.427365, 2026-03: 106.677,
Rev. CAGR: 34.80%
Rev. Trend: 98.0%
Last SUE: -0.01
Qual. Beats: 0

Warnings

Interest Coverage Ratio -0.5 is critical

Altman Z'' 0.83 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

Confidence

Description: IMCR Immunocore Holdings

Immunocore Holdings plc (IMCR) is a commercial-stage biotechnology company specializing in the development of T cell receptor (TCR) bispecific immunotherapies. The company’s lead product, KIMMTRAK, is established as a treatment for metastatic uveal melanoma. Its broader pipeline utilizes the proprietary ImmTAC platform to target oncology, infectious diseases, and autoimmune disorders, with multiple candidates currently in Phase 1 through Phase 3 clinical trials.

The biotechnology sector often requires high research and development expenditure, as companies must navigate rigorous multi-phase clinical trials and regulatory approvals before reaching commercialization. Immunocore’s business model focuses on leveraging TCR technology to redirect the immune system to recognize and kill cancer cells or virally infected cells that are often invisible to traditional antibody therapies.

For a deeper dive into the companys valuation metrics and financial health, consider checking ValueRay. Detailed analysis of clinical trial milestones is essential for assessing the long-term growth potential of clinical-stage biopharmaceutical firms.

Headlines to Watch Out For
  • KIMMTRAK commercial adoption in global markets drives near-term revenue growth
  • Clinical trial data for brenetafusp determines long-term cutaneous melanoma market share
  • Expansion into chronic infectious disease treatments impacts future valuation upside
  • Research and development spending levels influence cash runway and capital requirements
  • Regulatory approval timelines for PRAME-targeted oncology programs dictate stock volatility
Piotroski VR-10 (Strict) 1.0
Net Income: -18.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.78 > 1.0
NWC/Revenue: 198.0% < 20% (prev 239.7%; Δ -41.69% < -1%)
CFO/TA -0.02 > 3% & CFO -24.9m > Net Income -18.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.18 > 1.5 & < 3
Outstanding Shares: last quarter (52.9m) vs 12m ago 1.90% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 36.74% > 50% (prev 32.45%; Δ 4.29% > 0%)
Interest Coverage Ratio: -0.45 > 6 (EBITDA TTM -2.07m / Interest Expense TTM 11.5m)
Altman Z'' 0.83
A: 0.71 (Total Current Assets 1.00b - Total Current Liabilities 240.1m) / Total Assets 1.07b
B: -0.76 (Retained Earnings -818.3m / Total Assets 1.07b)
C: -0.00 (EBIT TTM -5.22m / Avg Total Assets 1.05b)
D: -1.26 (Book Value of Equity -853.5m / Total Liabilities 678.4m)
Altman-Z'' = 0.83 = B
Beneish M -3.07
DSRI: 1.11 (Receivables 81.1m/63.1m, Revenue 385.8m/333.6m)
GMI: 1.00 (GM 98.81% / 99.01%)
AQI: 0.57 (AQ_t 0.02 / AQ_t-1 0.03)
SGI: 1.16 (Revenue 385.8m / 333.6m)
TATA: 0.01 (NI -18.8m - CFO -24.9m) / TA 1.07b)
Beneish M = -3.07 (Cap -4..+1) = AA
What is the price of IMCR shares?

As of May 24, 2026, the stock is trading at USD 30.00 with a total of 243,992 shares traded.
Over the past week, the price has changed by +2.78%, over one month by -3.84%, over three months by -12.45% and over the past year by -7.63%.

Is IMCR a buy, sell or hold?

Immunocore Holdings has received a consensus analysts rating of 4.12. Therefore, it is recommended to buy IMCR.

  • StrongBuy: 8
  • Buy: 5
  • Hold: 3
  • Sell: 0
  • StrongSell: 1

What are the forecasts/targets for the IMCR price?
Analysts Target Price 63.5 111.6%
Immunocore Holdings (IMCR) - Fundamental Data Overview as of 20 May 2026
P/E Forward = 188.6792
P/S = 3.4957
P/B = 3.6656
Revenue TTM = 385.8m USD
EBIT TTM = -5.22m USD
EBITDA TTM = -2.07m USD
Long Term Debt = 393.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 438.7m USD (corrected: LT Debt 393.1m + ST Debt 2.00m) + Leases 43.6m
Net Debt = 2.99m USD (calculated: Debt 438.7m - CCE 435.7m)
Enterprise Value = 1.45b USD (1.44b + Debt 438.7m - CCE 435.7m)
Interest Coverage Ratio = -0.45 (Ebit TTM -5.22m / Interest Expense TTM 11.5m)
EV/FCF = 324.1x (Enterprise Value 1.45b / FCF TTM 4.46m)
FCF Yield = 0.31% (FCF TTM 4.46m / Enterprise Value 1.45b)
FCF Margin = 1.16% (FCF TTM 4.46m / Revenue TTM 385.8m)
Net Margin = -4.88% (Net Income TTM -18.8m / Revenue TTM 385.8m)
 Gross Margin = unknown ((Revenue TTM 385.8m - Cost of Revenue TTM 4.61m) / Revenue TTM)
 Tobins Q-Ratio = 1.35 (Enterprise Value 1.45b / Total Assets 1.07b)
Interest Expense / Debt = 2.62% (Interest Expense 11.5m / Debt 438.7m)
Taxrate = 2.26% (300k / 13.3m)
NOPAT = -5.10m (EBIT -5.22m * (1 - 2.26%)) [loss with tax shield]
Current Ratio = 3.71 (Total Current Assets 1.00b / Total Current Liabilities 270.3m)
Debt / Equity = 1.11 (Debt 438.7m / totalStockholderEquity, last quarter 393.7m)
 Debt / EBITDA = -1.44 (negative EBITDA) (Net Debt 2.99m / EBITDA -2.07m)
 Debt / FCF = 0.67 (Net Debt 2.99m / FCF TTM 4.46m)
Total Stockholder Equity = 389.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.79% (Net Income -18.8m / Total Assets 1.07b)
RoE = -1.56% (Net Income TTM -18.8m / Total Stockholder Equity 1.21b)
RoCE = -0.33% (EBIT -5.22m / Capital Employed (Equity 1.21b + L.T.Debt 393.1m))
 RoIC = -0.61% (negative operating profit) (NOPAT -5.10m / Invested Capital 834.0m)
 WACC = 6.24% (E(1.44b)/V(1.88b) * Re(7.36%) + D(438.7m)/V(1.88b) * Rd(2.62%) * (1-Tc(0.02)))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 3.60%
[DCF] Terminal Value 73.10% ; FCFF base≈7.60m ; Y1≈6.66m ; Y5≈5.38m
[DCF] Fair Price = 1.64 (EV 86.4m - Net Debt 2.99m = Equity 83.4m / Shares 50.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.39 | # QB: 1
Revenue Correlation: 98.02 | Revenue CAGR: 34.80% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.02 | Chg30d=+110.18% | Revisions=+33% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.01 | Chg30d=+93.92% | Revisions=+33% | Analysts=11
EPS current Year (2026-12-31): EPS=0.14 | Chg30d=+114.58% | Revisions=-8% | GrowthEPS=+119.2% | GrowthRev=+11.9%
EPS next Year (2027-12-31): EPS=-0.67 | Chg30d=+51.89% | Revisions=+9% | GrowthEPS=-702.2% | GrowthRev=+8.5%
[Analyst] Revisions Ratio: +33%